Filippo Testa

Dr. Filippo Testa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
NMNicolò Massironi
Nicolò Massironi
Miriam ColomboMiriam Colombo
Miriam Colombo
CCCesare Cosentino
Cesare Cosentino
FLFiandra Luisa
Fiandra Luisa
Michele MauriMichele Mauri
Michele Mauri
Israel VlodavskyIsrael Vlodavsky
Israel Vlodavsky
In this study, superparamagnetic iron oxide nanoparticles (SPIONs) were engineered with an organic coating composed of low molecular weight heparin (LMWH) and bovine serum albumin (BSA), providing heparin-based nanoparticle systems (LMWH@SPIONs). The purpose was to merge the properties of the heparin skeleton and an inorganic core to build up a targeted theranostic nanosystem, which was eventually enhanced by loading a chemotherapeutic agent. Iron oxide cores were prepared via the co-precipitation of iron salts in an alkaline environment and oleic acid (OA) capping. Dopamine (DA) was covalently linked to BSA and LMWH by amide linkages via carbodiimide coupling. The following ligand exchange reaction between the DA-BSA/DA-LMWH and OA was conducted in a biphasic system composed of water and hexane, affording LMWH@SPIONs stabilized in water by polystyrene sulfonate (PSS). Their size and morphology were investigated via dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively. The LMWH@SPIONs’ cytotoxicity was tested, showing marginal or no toxicity for samples prepared with PSS at concentrations of 50 µg/mL. Their inhibitory activity on the heparanase enzyme was measured, showing an effective inhibition at concentrations comparable to G4000 (N-desulfo-N-acetyl heparin, a non-anticoagulant and antiheparanase heparin derivative; Roneparstat). The LMWH@SPION encapsulation of paclitaxel (PTX) enhanced the antitumor effect of this chemotherapeutic on breast cancer cells, likely due to an improved internalization of the nanoformulated drug with respect to the free molecule. Lastly, time-domain NMR (TD-NMR) experiments were conducted on LMWH@SPIONs obtaining relaxivity values within the same order of magnitude as currently used commercial contrast agents.

6 December 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
ECEleonora Colombo
Eleonora Colombo
DCDavide Andrea Coppini
Davide Andrea Coppini
SMSimone Maculan
Simone Maculan
Pierfausto SeneciPierfausto Seneci
Pierfausto Seneci
BSBenedetta Santini
Benedetta Santini
DPDaniele Passarella
Daniele Passarella
Self-assembled hetero-nanoparticles are obtained by mixing paclitaxel and folic acid conjugates.

21 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LSLUCIA SALVIONI
LUCIA SALVIONI
FTFilippo Testa
Filippo Testa
LBLinda Barbieri
Linda Barbieri
MGMarco Davide Giustra
Marco Davide Giustra
JBJessica Armida Bertolini
Jessica Armida Bertolini
Miriam ColomboMiriam Colombo
Miriam Colombo
Ribosome-inactivating proteins, including Saporin toxin, have found application in the search for innovative alternative cancer therapies to conventional chemo- and radiotherapy. Saporin’s main mechanism of action involves the inhibition of cytoplasmic protein synthesis. Its strong theoretical efficacy is counterbalanced by negligible cell uptake and diffusion into the cytosol. In this work, we demonstrate that by immobilizing Saporin on iron oxide nanoparticles coated with an amphiphilic polymer, which promotes nanoconjugate endosomal escape, a strong cytotoxic effect mediated by ribosomal functional inactivation can be achieved. Cancer cell death was mediated by apoptosis dependent on nanoparticle concentration but independent of surface ligand density. The cytotoxic activity of Saporin-conjugated colloidal nanoparticles proved to be selective against three different cancer cell lines in comparison with healthy fibroblasts.

Verified
Journal Article
Open access
PDF file
Giulia TomainoGiulia Tomaino
Giulia Tomaino
CPCamilla Pantaleoni
Camilla Pantaleoni
ADAnnalisa D'Urzo
Annalisa D'Urzo
Carlo SantambrogioCarlo Santambrogio
Carlo Santambrogio
FTFilippo Testa
Filippo Testa
PTPaolo Tortora
Paolo Tortora
Vaults are eukaryotic ribonucleoproteins consisting of 78 copies of the major vault protein (MVP), which assemble into a nanoparticle with an about 60 nm volume-based size, enclosing other proteins and RNAs. Regardless of their physiological role(s), vaults represent ideal, natural hollow nanoparticles, which are produced by the assembly of the sole MVP. Here, we have expressed in Komagataella phaffi and purified an MVP variant carrying a C-terminal Z peptide (vault-Z), which can tightly bind an antibody’s Fc portion, in view of targeted delivery. Via surface plasmon resonance analysis, we could determine a 2.5 nM affinity to the monoclonal antibody Trastuzumab (Tz)/vault-Z 1:1 interaction. Then, we characterized the in-solution interaction via co-incubation, ultracentrifugation, and analysis of the pelleted proteins. This showed virtually irreversible binding up to an at least 10:1 Tz/vault-Z ratio. As a proof of concept, we labeled the Fc portion of Tz with a fluorophore and conjugated it with the nanoparticle, along with either Tz or Cetuximab, another monoclonal antibody. Thus, we could demonstrate antibody-dependent, selective uptake by the SKBR3 and MDA-MB 231 breast cancer cell lines. These investigations provide a novel, flexible technological platform that significantly extends vault-Z’s applications, in that it can be stably conjugated with finely adjusted amounts of antibodies as well as of other molecules, such as fluorophores, cell-targeting peptides, or drugs, using the Fc portion as a scaffold.

1 November 2021 in International Journal of Gynecological Cancer
Verified
Conference Paper
Open access
PDF file
EZE Van Der Zanden
E Van Der Zanden
FTFilippo Testa
Filippo Testa
CWC White
C White
SKS Kaushik
S Kaushik
PLP Larsen-Disney
P Larsen-Disney
SBS Baron
S Baron
Objectives To evaluate whether a consultant ‘buddy’ operating approach improves on intra-operative and post-operative outcomes in patients undergoing total laparoscopic hysterectomy (TLH) for endometrial cancer who are extremely and morbidly obese. Methods A prospectively selected cohort of 25 patients with a BMI 47–70 undergoing TLH was divided into two groups according to whether the first assistant to the Gynae-Oncology consultant was a registrar, or a consultant (‘buddy operating’). Anaesthetic time, operating time, intraoperative estimated blood loss (EBL), requirement for high dependency unit (HDU) bed and length of stay (LOS) were compared. Results Average ‘buddy’ operating time was significantly shorter compared to the registrar-assistant group (01:31h vs 01:59h respectively; p<0.001); a similar trend was seen with the average total anaesthetic time (02:48h vs 03:23h respectively; p<0.001). EBL was less in the ‘buddy operating’ group (39 mls) vs registrar-assistant group (169 mls; p<0.001). Post-operatively, LOS was shorter in the ‘buddy operating’ group as compared to the registrar-assistant, though not significantly so (1.13 vs 1.59 days; p=0.109). 2 of the total patients (8%) required a one-night stay in HDU for observation due to their co-morbidities, both in the registrar-assistant group. Mean BMI, age, ASA and comorbidities were similar in the two groups. Conclusions In patients with a significantly raised BMI, TLHs by two consultants vs consultant and registrar are associated with better intra and post-operative outcomes, including reduced overall anaesthetic time, operating time, and EBL. There is an association with a reduced length of overall hospital stay, though this was not significant.

10 July 2026 in ACS Applied Nano Materials
Verified
Journal Article
Open access
FTFilippo Testa
Filippo Testa
Andrea BanfiAndrea Banfi
Andrea Banfi
MGMarco Davide Giustra
Marco Davide Giustra
GTGiulia Tomaino
Giulia Tomaino
FLFiandra Luisa
Fiandra Luisa
Davide ProsperiDavide Prosperi
Davide Prosperi